The Europe rat model market is expected to grow from $XX thousand in 2018 to $XX thousand by the year 2027 at an anticipated CAGR of 7.67% for the forecast year 2019-2027. Improving genome editing techniques, rapid increase and ease in availability of results in transgenic rats and a growing interest of biotech and pharma companies in the market are the major drivers for the boom in the rat model market.
Germany has the largest market share in the European market owing to a large number of fiscal investments in research areas and profitable research related schemes. The market is broadly segmented into three categories: by type, by component and by the application. By type, the outbred rat type is expected to dominate the global rat model market with expected growth at a CAGR of XX%. By components, the services sector currently holds the largest market share, although the technology segment is anticipated to grow faster at a CAGR of xx% during the forecast period. But, the rules and regulations on the animal testing permit that allows the practice of non-human organisms for scientific research do fluctuate greatly throughout the world. This is expected to hamper the growth of the said market in future.
Research scientists and top pharmaceutical companies are increasingly using rat models for medical as well as clinical research. The top companies using these models are Oncodesign S.A., Vivo Biotech Ltd., Janvier Labs, Transviragen Inc., Genoway S.A., Charles River Laboratories Inc., Sage Labs Inc. (Acquired By Horizon Discovery Group PLC), Taconic Biosciences, Envigo, Clea Japan, Laboratory Corporation of America Holdings, Cyagen Biosciences Inc., Hera Biolabs Inc., Biomere and Transposagen Biopharmaceuticals Inc.